Albert David reports net loss in FY26
Albert David Limited reported a net loss of ₹149.47 lakh for FY26, a sharp reversal from the net profit of ₹1,720.08 lakh in FY25, as revenue fell to ₹33,359.81 lakh. The Board recommended a final dividend of ₹5.00 per share, subject to shareholder approval at the 87th AGM scheduled for August 6, 2026. The company has dispatched web-links for the Annual Report to shareholders with unregistered email addresses.

*this image is generated using AI for illustrative purposes only.
Albert David Limited reported a net loss of ₹149.47 lakh for the financial year ended March 31, 2026, compared to a net profit of ₹1,720.08 lakh in the previous fiscal year. Revenue from operations for the period declined to ₹33,359.81 lakh from ₹34,576.79 lakh in FY25. The company’s Profit Before Tax (PBT) stood at ₹52.49 lakh, a significant decrease from ₹2,522.77 lakh in the previous year. Total income for FY26 was reported at ₹34,105.14 lakh. The Board has recommended a final dividend of ₹5.00 per equity share of ₹10 each, subject to shareholder approval at the Annual General Meeting.
The financial performance for the year reflects a decline in profitability despite operational efforts. The company stated that it invested in strengthening its field force during the year to support future growth, which impacted the current financial results. Earnings Per Share (EPS) for the year stood at (₹2.62) compared to ₹30.14 in the previous year.
Financial Performance
| Financial Parameters (Rs. in Lakhs) | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue from Operations | 33,359.81 | 34,576.79 |
| Total Income | 34,105.14 | 37,534.87 |
| Profit Before Tax | 52.49 | 2,522.77 |
| Net Profit / (Loss) | (149.47) | 1,720.08 |
| Earnings Per Share (₹) | (2.62) | 30.14 |
Operational Highlights
During the year, Albert David focused on strengthening its product line and widening its clientele. The company’s flagship brand, Placentrex, continued to be a primary growth lever, contributing over 30% of revenues. The company also advanced its research and development initiatives, particularly in mapping bioconstituents with IIT Kharagpur.
Corporate Updates
The Board of Directors, in its meeting held on May 12, 2026, approved the financial statements for the year. The company’s auditors, M/s. L. B. Jha & Co., Chartered Accountants, issued an unqualified report on the financial statements. The 87th Annual General Meeting (AGM) of the company will be held on August 6, 2026, at 9.30 A.M IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company has completed the dispatch of letters containing the web-link to the Annual Report for the financial year 2025–26 to members whose e-mail addresses were not registered with the Company or Depositories.
Historical Stock Returns for Albert David
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.44% | -0.08% | -3.76% | -1.50% | -24.70% | +27.75% |
What is the expected timeline for the strengthened field force to translate into tangible revenue growth?
How will the company balance the proposed dividend payout with its current net loss position and cash flow requirements?
What specific new products or market segments is Albert David targeting to diversify beyond its reliance on the Placentrex brand?































